Study Rationale, Enrollment Characteristics, and Central Review of Clinical Stage: The INTACT Randomized Clinical Trial

Importance: Trimodality therapy (TMT) is an established bladder-preservation approach for muscle-invasive bladder cancer (MIBC). Accurate clinical staging remains challenging and may affect patient selection, trial design, and interpretation of outcomes. Objective: To describe the design, accrual, and baseline characteristics of the Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (INTACT) trial and evaluate agreement between site-reported and centrally reviewed clinical stage and the prevalence of high-risk disease features. Design, Setting, and Participants: INTACT is a phase 3 randomized clinical trial that enrolled patients with localized MIBC (stage cT2-T4aN0M0) at 136 US sites between April 2019 and March 2025. For this analysis, 243 patients with available source documentation were randomly selected by the SWOG Statistical Center for central clinical staging review. Interventions: Patients were randomized to physician's choice of concurrent chemotherapy (cisplatin, gemcitabine, or 5-fluorouracil and mitomycin C) and radiotherapy (bladder only or small pelvis; 64-64.8 Gy), with or without atezolizumab (1200 mg intravenously every 3 weeks for 9 cycles). Main Outcomes and Measures: The trial's primary end point is 3-year bladder-intact event-free survival, which is not reported in this analysis. Outcomes for the present analysis included trial accrual, clinical stage distribution, agreement between site-reported stage and the initial independent central reviewer, and prevalence of predefined high-risk features (carcinoma in situ, unilateral hydronephrosis, or tumor >5 cm). Agreement was assessed using Cohen κ and directional disagreement using the McNemar test. Results: Among 485 randomized patients, the median (IQR) age was 73.8 (37.6-93.6) years, 384 (79.2%) were male, 16 (3.3%) were Asian, 33 (6.8%) were Black, and 419 (86.4%) were White. Site investigators classified 398 (82.1%) as stage cT2 and 87 (17.9%) as stage cT3 or T4a. Among 243 patients selected for central review, 201 (82.7%) had site-reported stage cT2 disease and 42 (17.3%) had stage cT3 or T4a disease. Agreement between site-reported stage and the initial independent central reviewer was moderate (κ = 0.48; 95% CI, 0.34-0.62). Of 201 site-reported stage cT2 cases, 24 (11.9%) were assigned stage cT3 or T4a by the central reviewer; of 42 site-reported stage cT3 or T4a cases, 15 (35.7%) were assigned stage cT2. Among patients with site-reported stage cT2 disease, 113 (56.2%) had at least 1 high-risk feature. Overall, 155 of 243 patients (63.8%) had at least 1 high-risk feature. Conclusions and Relevance: In this phase 3 randomized clinical trial, a pragmatic design facilitated accrual of 485 patients to a US bladder-preservation trial. Clinical staging showed moderate agreement between site investigators and independent central review, and more than half of patients classified as stage cT2 had additional high-risk features. These findings support standardized collection of clinical staging and high-risk disease characteristics in future bladder-preservation trials. Trial Registration: ClinicalTrials.gov Identifier: NCT03775265.

Authors

Institutions

Publication Details

Journal
JAMA Network Open
Published
2026-11-16
DOI
https://doi.org/10.1001/jamanetworkopen.2026.44122
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Study Rationale, Enrollment Characteristics, and Central Review of Clinical Stage: The INTACT Randomized Clinical Trial

Xinglei Shen, Mamta Parikh, Paul Linh Nguyen, Sean Sachdev et al.
1 links
JAMA Network Open
Bladder and Urothelial Cancer Treatments
article

Study Rationale, Enrollment Characteristics, and Central Review of Clinical Stage: The INTACT Randomized Clinical Trial

Xinglei Shen, Mamta Parikh, Paul Linh Nguyen, Sean Sachdev, Sameer G. Jhavar, Burles Avner Johnson, Siamak Daneshmand, Seth P. Lerner, Monika Joshi, Jason Palopoli, Austin Kirchner, Paul Mehan, Maged F. Khalil, Catherine Tangen, Ashesh Jani, Daniel Petrylak, Kent W. Mouw, Brian Cross, Jason Efsthathiou, Ian Thompson, Adam Olson, Brian Costello, Scott Delacroix, Leslie K. Ballas, Melissa Plets, Petros Grivas, Parminder Singh, Carie Marquette
article en

Abstract

Importance: Trimodality therapy (TMT) is an established bladder-preservation approach for muscle-invasive bladder cancer (MIBC). Accurate clinical staging remains challenging and may affect patient selection, trial design, and interpretation of outcomes. Objective: To describe the design, accrual, and baseline characteristics of the Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (INTACT) trial and evaluate agreement between site-reported and centrally reviewed clinical stage and the prevalence of high-risk disease features. Design, Setting, and Participants: INTACT is a phase 3 randomized clinical trial that enrolled patients with localized MIBC (stage cT2-T4aN0M0) at 136 US sites between April 2019 and March 2025. For this analysis, 243 patients with available source documentation were randomly selected by the SWOG Statistical Center for central clinical staging review. Interventions: Patients were randomized to physician's choice of concurrent chemotherapy (cisplatin, gemcitabine, or 5-fluorouracil and mitomycin C) and radiotherapy (bladder only or small pelvis; 64-64.8 Gy), with or without atezolizumab (1200 mg intravenously every 3 weeks for 9 cycles). Main Outcomes and Measures: The trial's primary end point is 3-year bladder-intact event-free survival, which is not reported in this analysis. Outcomes for the present analysis included trial accrual, clinical stage distribution, agreement between site-reported stage and the initial independent central reviewer, and prevalence of predefined high-risk features (carcinoma in situ, unilateral hydronephrosis, or tumor >5 cm). Agreement was assessed using Cohen κ and directional disagreement using the McNemar test. Results: Among 485 randomized patients, the median (IQR) age was 73.8 (37.6-93.6) years, 384 (79.2%) were male, 16 (3.3%) were Asian, 33 (6.8%) were Black, and 419 (86.4%) were White. Site investigators classified 398 (82.1%) as stage cT2 and 87 (17.9%) as stage cT3 or T4a. Among 243 patients selected for central review, 201 (82.7%) had site-reported stage cT2 disease and 42 (17.3%) had stage cT3 or T4a disease. Agreement between site-reported stage and the initial independent central reviewer was moderate (κ = 0.48; 95% CI, 0.34-0.62). Of 201 site-reported stage cT2 cases, 24 (11.9%) were assigned stage cT3 or T4a by the central reviewer; of 42 site-reported stage cT3 or T4a cases, 15 (35.7%) were assigned stage cT2. Among patients with site-reported stage cT2 disease, 113 (56.2%) had at least 1 high-risk feature. Overall, 155 of 243 patients (63.8%) had at least 1 high-risk feature. Conclusions and Relevance: In this phase 3 randomized clinical trial, a pragmatic design facilitated accrual of 485 patients to a US bladder-preservation trial. Clinical staging showed moderate agreement between site investigators and independent central review, and more than half of patients classified as stage cT2 had additional high-risk features. These findings support standardized collection of clinical staging and high-risk disease characteristics in future bladder-preservation trials. Trial Registration: ClinicalTrials.gov Identifier: NCT03775265.

JAMA Network OpenVol. 9(11)
Northwestern University (US), Christiana Care Health System (US), Cedars-Sinai Medical Center (US), Mayo Clinic (US), Harvard University (US), Johns Hopkins University (US), Thomas Jefferson University (US), The University of Texas at San Antonio Health Science Center (US), Baylor College of Medicine (US), University of Washington (US), Missouri Baptist Medical Center (US), Yale University (US), Massachusetts General Hospital (US), Fred Hutch Cancer Center (US), USC Norris Comprehensive Cancer Center (US), Mayo Clinic in Arizona (US), UPMC Hillman Cancer Center (US), University of Kansas Medical Center (US), Scott & White Memorial Hospital (US), Lehigh Valley Hospital (US), University of Pittsburgh Medical Center (US), Mary Bird Perkins Cancer Center (US), SWOG Cancer Research Network (US), Winship Cancer Institute (US), UC Davis Comprehensive Cancer Center (US), OU Health Stephenson Cancer Center (US), Penn State Cancer Institute (US), Penn State Milton S. Hershey Medical Center (US), University of Oklahoma (US), Vanderbilt University Medical Center (US), Texas A&M University (US)
Good health and well-being
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon